Publicacións en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (19)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Genetic and immune landscape evolution in MMR-deficient colorectal cancer

    Journal of Pathology

  3. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

    JNCI Cancer Spectrum, Vol. 7, Núm. 6

2022

  1. Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer

    Radiotherapy and Oncology, Vol. 176, pp. 138-148

  2. No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity

    International Journal of Radiation Oncology Biology Physics, Vol. 114, Núm. 3, pp. 494-501

2021

  1. A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy

    Computers in Biology and Medicine, Vol. 135

2020

  1. Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients – results from the REQUITE cohort study

    European Journal of Cancer, Vol. 138, pp. S12

2019

  1. Association analyses identify 31 new risk loci for colorectal cancer susceptibility

    Nature Communications, Vol. 10, Núm. 1

  2. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer

    European Journal of Cancer, Vol. 117, pp. 60-68

2017

  1. Gefitinib and EGFR gene copy number aberrations in esophageal cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287

2014

  1. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity

    Radiotherapy and Oncology, Vol. 111, Núm. 2, pp. 178-185

  2. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904

  3. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 829-840

  4. Phase II trial of cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study

    Translational Oncology, Vol. 7, Núm. 1, pp. 55-64

  5. The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors

    Clinical Oncology

2011

  1. Current management practices for acromegaly: An international survey

    Pituitary, Vol. 14, Núm. 2, pp. 125-133

2010

  1. A consensus on criteria for cure of acromegaly

    Journal of Clinical Endocrinology and Metabolism

2009

  1. Cribriform-morular variant of papillary thyroid carcinoma molecular characterization of a case with neuroendocrine differentiation and aggressive behavior

    American Journal of Clinical Pathology, Vol. 131, Núm. 1, pp. 134-142

2006

  1. Effect of growth hormone in an experimental model of protein hypercatabolism induced by glucocorticoids

    Hormone and Metabolic Research, Vol. 38, Núm. 9, pp. 556-562